98-28-2

Basic information

• Product Name: 4-TERT-BUTYL-2-CHLOROPHENOL
• Synonyms: 4-TERT-BUTYL-2-CHLOROPHENOL;2-CHLORO-4-TERT-BUTYLPHENOL;phenol, 2-chloro, 4-t-butyl;Phenol, 4-tert-butyl-2-chloro-;4-TERT-BUTYL-2-CHLOROPHENOL, 10MG, NEAT;NSC 8464;4-TERT-BUTYL-2-CHLOROPHENOL: TECH., 90%
• CAS NO: 98-28-2
• Molecular Formula: C₁₀H₁₃ClO
• Molecular Weight: 184.66
• EINECS: 202-652-3
• Product Categories: A-BAlphabetic;Alpha sort;B;BI - BZEnvironmental Standards;Metabolites;Pesticides&Metabolites
• Mol File: 98-28-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 238.7°Cat760mmHg
• Flash Point: 98.2°C
• Appearance: /
• Density: 1.109g/cm³
• Vapor Pressure: 0.0271mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• PKA: 8.71±0.18(Predicted)
• CAS DataBase Reference: 4-TERT-BUTYL-2-CHLOROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-TERT-BUTYL-2-CHLOROPHENOL(98-28-2)
• EPA Substance Registry System: 4-TERT-BUTYL-2-CHLOROPHENOL(98-28-2)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-41-37/38-22
• Safety Statements: 36/37-45-39-26
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 98-28-2(Hazardous Substances Data)

Usage

Uses

4-tert-Butyl-2-chlorophenol is a colorless liquid that used in organic synthesis.

InChI:InChI=1/C10H13ClO/c1-10(2,3)7-4-5-9(12)8(11)6-7/h4-6,12H,1-3H3

Upstream product

• 95-57-8 2-monochlorophenol 
• 115-11-7 isobutene 
• 75-65-0 tert-butyl alcohol 
• 96-76-4 2,4-di-tert-Butylphenol 
• 76-05-1 trifluoroacetic acid 
• 98-54-4 para-tert-butylphenol 
• 939-97-9 4-tert-Butylbenzaldehyde 
• 598-49-2 N-chloroacetamide 
• 107-39-1 2,4,4-trimethyl-1-pentene 

Downstream Products

• 102475-98-9 4-tert-butyl-2-chloro-6-piperidinomethyl-phenol 
• 802-62-0 4,4'-di-tert-butyl-6,6'-dichloro-2,2'-methanediyl-di-phenol 
• 101876-79-3 4-tert-butyl-6,4',6'-trichloro-2,2'-methanediyl-di-phenol 
• 2051-63-0 (4-tert-butyl-2-chloro-phenyl)-(2-chloro-ethyl)-ether 
• 100388-76-9 acetic acid-(4-tert-butyl-2-chloro-phenyl ester) 
• 7598-31-4 toluene-4-sulfonic acid-(4-tert-butyl-2-chloro-phenyl ester) 
• 52330-46-8 C₁₇H₂₇ClNO₄PS 
• 34704-82-0 C₁₅H₂₃ClNO₂PS 
• 33348-28-6 Thiophosphoric acid O-(4-tert-butyl-2-chloro-phenyl) ester S-(2-ethoxy-ethyl) ester O'-ethyl ester 
• 69183-12-6 (4-tert-Butyl-2-chloro-phenoxy)-{4-[3-(4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid 
• 34694-01-4 C₁₄H₂₁ClNO₂PS 
• 33348-30-0 Thiophosphoric acid O-(4-tert-butyl-2-chloro-phenyl) ester O'-ethyl ester S-(2-isopropoxy-ethyl) ester 
• 33348-29-7 Thiophosphoric acid O-(4-tert-butyl-2-chloro-phenyl) ester O'-ethyl ester S-(2-propoxy-ethyl) ester 
• 1078600-03-9 6-[(4-tert-butyl-2-chlorophenoxy)methyl][1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid 

Relevant articles and documents

In situ Generation of Hypervalent Iodine Reagents for the Electrophilic Chlorination of Arenes

Efficient metal-free methods for the electrophilic chlorination of arenes using PIFA and simple chlorine sources are reported. The in situ formation of PhI(Cl)OCOCF3 from PIFA and KCl is proposed, which resulted in a chlorinating species for moderately activated arenes. Moreover, the in situ formation of PhICl2 from PIFA and TMSCl resulted in an excellent approach for the chlorination of a great variety of arenes (20 examples) in high yields, even when working on a multigram scale.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.